<DOC>
	<DOCNO>NCT01818063</DOCNO>
	<brief_summary>This randomized phase II trial study well carboplatin combination chemotherapy without veliparib work treat patient stage IIB-IIIC breast cancer . Drugs use chemotherapy , paclitaxel , carboplatin , doxorubicin hydrochloride , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop dividing . Veliparib may stop growth tumor cell block enzymes need cell growth . It yet know whether give carboplatin combination chemotherapy effective without veliparib effective treat breast cancer .</brief_summary>
	<brief_title>Carboplatin Combination Chemotherapy With Without Veliparib Treating Patients With Stage IIB-IIIC Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : 1 ) To compare pathologic complete response ( path CR ) patient stage IIB stage III triple negative breast cancer treat neoadjuvant paclitaxel carboplatin path CR patient treat paclitaxel , carboplatin , veliparib . SECONDARY OBJECTIVES : 1 . Relapse free survival ( follow-up period 36 month ) . 2 . Overall clinical response neoadjuvant therapy . 3 . To determine whether expression 5 biomarkers ( cytokeratin [ CK ] 5 , endothelial growth factor receptor [ EGFR ] , excision repair cross complement 1 [ ERCC1 ] , Ki67 , poly [ adenosine diphosphate ( ADP ) -ribosyl ] transferase [ Parp1 ] ) correlate high pCR response particular treatment combination . 4 ) To determine whether tumor biomarker signature like breast cancer ( BRCA ) -mutated tumor ( high expression CK5 high expression EGFR ) , correlate high likelihood pCR treatment PARP inhibitor combination chemotherapy . 5 ) To determine whether tumor high expression marker ERCC1 , Ki67 , Parp1 correlate high rate pCR platinum agent combination paclitaxel PARP inhibitor . 6 ) To correlate response tumor imaging ( magnetic resonance image [ MRI ] , ultrasound [ US ] , positron emission tomography [ PET ] /computed tomography [ CT ] ) path CR . 7 ) To correlate level circulate tumor cell ( CTCs ) pathologic CR . TERTIARY OBJECTIVES : 1 . To evaluate additional exploratory biomarkers base evidence possible prognostic predictive value : BRCA1/BRCA2 complete mutational rearrangement test . CK14 , CK17 , cyclin B1 , cluster differentiation ( CD ) 44 , CD24 , cyclin D1 , vimentin , thymidine phosphorylase , inhibitor differentiation ( ID ) 4 , p53 , p63 , p73 , differentiate embryo-chondrocyte express gene ( Dec ) 1 , phospho-HistoneH3 , thymidylate synthase , p16 , gammaH2AX , geminin , RAD51 . 2 . To determine arm best tolerate patient co-morbid condition , hypertension diabetes . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive paclitaxel intravenously ( IV ) carboplatin IV day 1 ( course 1 ) day 2 ( course 2-12 ) . Treatment repeat every 7 day 12 course absence disease progression unacceptable toxicity . Beginning 21 day last course , patient receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . ARM II : Patients receive veliparib orally ( PO ) twice daily ( BID ) day 1-5 . Patients also receive paclitaxel IV carboplatin IV day 3 ( course 1 ) day 4 ( course 2-12 ) . Treatment repeat every 7 day 12 course absence disease progression unacceptable toxicity . Beginning 21 day last course , patient receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 36 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Written informed consent must obtain prior studyrelated procedure . 2 . Histologically confirm adenocarcinoma breast follow marker : Estrogen receptor negative ( &lt; 1 % ) , progesterone receptor negative ( &lt; 1 % ) , Her2/neu negative ( Her2/neu 01+ IHC FISH ratio &lt; 1.8 average HER2 gene copy number &lt; four signal/nucleus test system without internal control probe ) . 3 . Female ≥ 18 year old . 4 . Clinical stage IIA ( T2N0 ) , IIB ( T2N1 , T3N0 ) stage IIIA ( T1N2 , T2N2 , T3N1 , T3N2 ) , IIIB , IIIC breast cancer prior treatment . 5 . Complete radiology tumor assessment within 28 day prior enrollment 1 . Breast MRI 2 . Unilateral Breast Ultrasound 3 . Distant metastatic workup complete PET/CT . 4 . If enlarge axillary lymph node find stag scan , FNA must perform determine whether node involved cancer . 5 . If axillary lymph node clinically negative initial workup , sentinel node biopsy perform prior initiation chemotherapy . 6 . ECOG Performance Status 0 1 7 . Adequate organ hematologic function evidence follow laboratory study within 4 week study enrollment : 1 . Cardiac Ejection Fraction &gt; /= low limit normal determine 2D echo MUGA scan accord institutional standard . 2 . Hematologic function , follow : Absolute neutrophil count ≥ 1.5 x 109/L , Platelet count ≥ 100 x 109/L ≤ 850 x 109/L , Hemoglobin ≥ 9 g/dL , PTT INR &lt; 1.5 x ULN . 3 . Renal function , follow : Serum creatinine &lt; /= 1.4 mg/dL ) . 4 . Hepatic function , follow : Aspartate aminotransferase ( AST ) ≤ 2.5 x ULN , Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN , Total bilirubin ≤ 2 x ULN ( except patient UGT1A1 promoter polymorphism , i.e . Gilbert syndrome , confirm genotyping Invader UGT1A1 molecular assay prior study enrollment . Patients enrol Gilbert syndrome must total bilirubin &lt; 3 ULN ) . 8 . Patient must willing able undergo MRI outline protocol . 1 . Known hypersensitivity doxorubicin , cyclophosphamide , paclitaxel , cremophor medication contain cremophor ( miconazole , docetaxel , sandimmune , nelfinavir mesylate , propofol , diazepam injection , vitamin K injection , ixabepilone , acijel ) carboplatin . 2 . Known HIV active Hepatitis B C infection . 3 . Prior treatment currently diagnose breast cancer . 4 . Prior treatment doxorubicin 400 mg/m2 . 5 . Preexisting Grade 3 4 sensory neuropathy . 6 . History bleed diathesis extensive bleeding require blood transfusion within 14 day enrollment . 7 . Major surgical procedure within 4 week ( 28 day ) prior enrollment ( port placement consider major surgical procedure ) . 8 . Clinically significant cardiac disease within 12 month study enrollment , include myocardial infarction , unstable angina , congestive heart failure , ongoing arrhythmias require medication pacemaker . 9 . Nonhealing wound , ulcer fracture . 10 . Ongoing active infection . 11 . Pregnant ( i.e. , positive betahuman chorionic gonadotropin test ) lactate 12 . Not willing use highly effective method birth control ( i.e . result low failure rate , le 1 % per year ) , define intrauterine device , barrier method ( condom , contraceptive sponge , diaphragm , vaginal ring use spermicidal jelly cream ) , oral contraceptive pill , sexual abstinence . Contraception must use study . 13 . T0 tumor 14 . Active dental infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>